Nine Chapters Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Nine Chapters Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-28,300	Closed	-$211K	–	1261
2015 Q2	$211K	Sell	28,300 -17,200	-38%	-$104K	0.02%	803
2015 Q1	$272K	Sell	45,500 -9,800	-18%	-$61.7K	0.02%	744
2014 Q4	$418K	Buy	+55,300	New	+$331K	0.04%	588
2014 Q2	–	Sell	-44,100	Closed	-$180K	–	1192
2014 Q1	$180K	Buy	+44,100	New	+$226K	0.02%	730
2013 Q4	–	Sell	-12,200	Closed	-$61K	–	992
2013 Q3	$61K	Sell	12,200 -4,500	-27%	-$24.4K	0.01%	709
2013 Q2	$74K	Buy	+16,700	New	+$74.9K	0.01%	601

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nine Chapters Capital Management's PGNX Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2015, closing a stake of 28,300 shares — an estimated $211K sold.

Nine Chapters Capital Management first reported a position in PGNX in Q2 2013 and held it in 6 quarters. The position peaked at $418K in Q4 2014. 133 funds tracked by Wall St. Rank hold PGNX as of Q3 2015.

Nine Chapters Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 28,300 Progenics Pharmaceuticals Inc shares in Q3 2015, an estimated $211K.
Nine Chapters Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 6 quarters.
Nine Chapters Capital Management's Progenics Pharmaceuticals Inc position peaked at $418K in Q4 2014.
133 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.